We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Urine Test Developed for Congenital Chagas Disease

By LabMedica International staff writers
Posted on 09 Nov 2014
A Chagas urine nanoparticle test (Chunap) has been developed to concentrate, preserve and detect Trypanosoma cruzi antigens in urine for early, noninvasive diagnosis of congenital Chagas disease.

The conventional diagnosis of congenital Chagas disease is based on microscopy at birth and serology at nine months; however microscopy misses many infections and many at-risk infants fail to complete serology at six to nine months.

A team of international scientists led by those at Johns Hopkins University (Baltimore, MD, USA) collected 74 urine samples from Bolivian infants without congenital infection and 23 specimens from infants with congenital infection whose urine collection occurred prior to initiation of antitrypanosomal treatment. More...
Urine samples from 12 seronegative infants from Lima (Peru) were collected as non-endemic negative controls. Blood samples from infants obtained at birth and one month were evaluated by the micromethod, using a microscope, and polymerase chain reaction (PCR).

The screening specimens were tested by two rapid diagnostic tests (RDTs): an indirect hemagglutination test (IHA), and Chagas Detect, an immunochromatographic strip assay (InBios International; Seattle, WA, USA). The team evaluated the ability of the Poly N-isopropylacrylamide nanoparticles functionalized with trypan blue and synthesized by precipitation polymerization and characterized with photon correlation spectroscopy, to capture, concentrate and preserve T. cruzi antigens.

Urine samples from congenitally infected and uninfected infants were then concentrated using these nanoparticles. The antigens were eluted and detected by Western Blot using a monoclonal antibody against T. cruzi lipophosphoglycan. Visualization of antigenic bands was done using an enhanced chemiluminescence system (Supersignal West Dura, Thermo Fisher Scientific; Rockford, IL, USA). The Chunap test was carried out by a laboratory biologist who was also blinded to the Chagas status of the patient.

The nanoparticles concentrated T. cruzi antigens by 100 fold with the western blot detection limit decreased from 50 ng/mL to 0.5 ng/mL. The sensitivity of Chunap in a single specimen at one month of age was 91.3% (21/23) comparable to PCR in two specimens at birth and one month and significantly higher than microscopy in two specimens. Chunap specificity was 96.5%, 71/74 for endemic, 12/12 for non-endemic specimens. The cumulative sensitivity of micromethod and PCR was 34.8% (8/23) and 91.3% (21/23), respectively. Particle-sequestered T. cruzi antigens were protected from trypsin digestion.

The authors concluded that Chunap has the potential to enable early point-of-care diagnosis of congenital Chagas disease in peripheral health facilities. Further steps will be necessary to apply this nanotechnology in developing countries. The team is currently optimizing a novel separation method based on magnetic labeling of capturing nanoparticles to enable particle separation from urine without the need for a high speed centrifuge. Although used in this study for Chagas disease, this method could be adapted for detection of other parasitic infections in urine and other body fluids. The study was published on October 2, 2014 in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Johns Hopkins University 
InBios International
Thermo Fisher Scientific 



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.